Oligochlorophens Are Potent Inhibitors of Bacillus anthracis-Reference-Cited by-同舟云学术

Oligochlorophens Are Potent Inhibitors of Bacillus anthracis

Published:2010-09 Issue:9 Volume:54 Page:3988-3990
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Foss Marie H.¹,Weibel Douglas B.¹²

Affiliation:

1. Department of Biochemistry

2. Department of Biomedical Engineering, University of Wisconsin—Madison, Madison, Wisconsin

Abstract

ABSTRACT Bacterial cytoskeletal proteins are an emerging set of targets for antibiotic development. This paper describes oligochlorophen analogs based on the monomer 4-chloro-2,6-dimethylphenol as antimicrobial agents against Bacillus anthracis . The most potent analogs have a MIC of 160 to 320 nM against B. anthracis and may target the cytoskeletal protein FtsZ. B. anthracis develops resistance to the oligochlorophens at a rate of 4.34 × 10 −10 per generation, which is ∼10-fold lower than that of commercial antibiotics used to treat this human pathogen.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00067-10

Reference19 articles.

1. Antibiotic resistance: an ecological perspective on an old problem. 2009

2. Athamna, A., M. Athamna, N. Abu-Rashed, B. Medlej, D. J. Bast, and E. Rubinstein. 2004. Selection of Bacillus anthracis isolates resistant to antibiotics. J. Antimicrob. Chemother.54:424-428.

3. Beaver, D. J., R. S. Shumard, and P. J. Stoffel. 1953. Preparation and bacteriostatic properties of substituted trisphenols. J. Am. Chem. Soc.75:5579-5581.

4. In Vitro Development of Resistance to Ofloxacin and Doxycycline in Bacillus anthracis Sterne

5. Ely, B. 1991. Genetics of Caulobacter crescentus. Methods Enzymol.204:372-384.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combating biothreat pathogens: ongoing efforts for countermeasure development and unique challenges;Drug Discovery Targeting Drug-Resistant Bacteria;2020

2. Alternative pre-approved and novel therapies for the treatment of anthrax;BMC Infectious Diseases;2016-11-03

3. Bacillus anthracis infections – new possibilities of treatment;Annals of Agricultural and Environmental Medicine;2015-05-11

4. Inhibitors of Bacterial Cell Partitioning;Antibiotics;2013-10-04

5. Inhibitors of bacterial tubulin target bacterial membranes in vivo;MedChemComm;2013